In the News
The Food and Drug Administration recently announced the approval of a new preventative drug called Beyfortus to be used for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in newborns and infants. “While all children will eventually get an RSV illness, reducing those infections in the youngest and most vulnerable infants is key,” said Tom Truman, M.D., specialty medical officer for pediatric critical care medicine at Pediatrix® Medical Group. “The COVID experience showed us very well that RSV and other contagious viral illnesses are just a part of doing business in our society, and Beyfortus will reduce that cost of doing business by preventing or reducing serious disease in our youngest, most vulnerable children.”
View the full story on Healthline